Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS

Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Shanghai RAAS, one of China's largest blood plasma companies, for $1.9 billion in a non-cash deal. Ambrx, a San Diego ...

Read the original article: shanghai china - BingNews